SCHEMBL20775376

SCHEMBL20775376

Cn1ncc2ccc(NS(=O)(=O)C3CCCC3)cc21

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 2/20 0.58
SYK P43405 1/20 0.43
ABL1 P00519 1/20 0.42
BRD4 O60885 5/20 0.41
BRAF P15056 1/20 0.40
EML4 Q9HC35 1/20 0.40
ALK Q9UM73 1/20 0.40
CYP2C9 P11712 1/20 0.39
NAMPT P43490 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
CREBBP Q92793 1/20 0.39
SGK1 O00141 1/20 0.39
PTGER3 P43115 1/20 0.39
CYP17A1 P05093 1/20 0.39
JAK1 P23458 1/20 0.39
CYP1A2 P05177 1/20 0.38
GRM4 Q14833 1/20 0.38
MLLT1 Q03111 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20782358 0.99 BRPF1 (0.60) BRPF1SYKABL1BRD4BRAF
SCHEMBL22126774 0.97 BRPF1 (0.55) BRPF1SYKABL1BRD4BRAF
SCHEMBL20769912 0.95 BRPF1 (0.57) BRPF1SYKBRD4BRAFEML4
SCHEMBL20769998 0.86 BRPF1 (0.49) BRPF1SYKBRD4BRAFEML4
SCHEMBL31039593 0.81 MEN1 (0.42) BRPF1SYKBRD4BRAFEML4
SCHEMBL20771719 0.81 MEN1 (0.42) BRPF1SYKBRD4BRAFEML4
SCHEMBL22126773 0.79 ALDH1A1 (0.53) BRPF1BRD4NAMPTTRPV1CREBBP
SCHEMBL19260071 0.78 CA1 (0.49) BRPF1BRD4EML4ALKNAMPT
SCHEMBL18424298 0.78 BRPF1 (0.56) BRPF1BRD4NAMPTTRPV1CREBBP
SCHEMBL20769933 0.77 FKBP1A (0.53) BRD4TRPV1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3676255-B1 THERAPEUTIC INDAZOLES RUTGERS THE STATE UNIV UNIV OF NEW JERSEY (US) 2025-04-16 EP disclosed
US-12060330-B2 Therapeutic indazoles RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-08-13 US disclosed
US-20220144781-A1 THERAPEUTIC INDAZOLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2022-05-12 US disclosed
US-11186549-B2 Therapeutic indazoles RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2021-11-30 US disclosed
EP-3676255-A1 THERAPEUTIC INDAZOLES Rutgers, The State University University Of New Jersey (US) 2020-07-08 EP disclosed
US-20200199076-A1 THERAPEUTIC INDAZOLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-06-25 US disclosed
WO-2019046467-A1 THERAPEUTIC INDAZOLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060330-B2 Therapeutic indazoles RIF1, QTRT1, NQO2 BRPF1 1472/4885SYK 1790/4885ABL1 25/4885
US-20220144781-A1 THERAPEUTIC INDAZOLES RIF1, QTRT1, NQO2 BRPF1 1472/4885SYK 1790/4885ABL1 25/4885
US-20200199076-A1 THERAPEUTIC INDAZOLES RIF1, NQO2, QTRT1 BRPF1 1554/4885SYK 1676/4885ABL1 12/4885
US-11186549-B2 Therapeutic indazoles RIF1, NQO2, QTRT1 BRPF1 1554/4885SYK 1676/4885ABL1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.